Premium
Reduced‐intensity conditioning–based hematopoietic cell transplantation for dyskeratosis congenita: Single‐center experience and literature review
Author(s) -
Bhoopalan Senthil Velan,
Wlodarski Marcin,
Reiss Ulrike,
Triplett Brandon,
Sharma Akshay
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.29177
Subject(s) - medicine , regimen , dyskeratosis congenita , transplantation , fludarabine , surgery , hematopoietic stem cell transplantation , gastroenterology , graft versus host disease , single center , oncology , chemotherapy , cyclophosphamide , dna , telomere , biology , genetics
Background Bone marrow failure in dyskeratosis congenita (DKC) is progressive, and allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment. However, outcomes after HCT are suboptimal because of mucosal, vascular, pulmonary, and hepatic fragility, which can be exacerbated by chemotherapy conditioning and graft‐versus‐host disease (GVHD). These toxicities can be mitigated by reducing the intensity of the conditioning regimen. Procedures We performed a retrospective analysis on pediatric patients with DKC who underwent HCT at our institution between 2008 and 2019. Results We identified nine patients (median age, 5.7 years) who underwent HCT with a fludarabine‐based reduced‐intensity conditioning (RIC) regimen. GVHD prophylaxis consisted of tacrolimus plus mycophenolate mofetil (MMF) ( n = 8), tacrolimus/pentostatin ( n = 1), or cyclosporine/MMF ( n = 1). The median time to neutrophil engraftment was 19 days (range, 13‐26 days), and the median time to platelet engraftment was 18 days (range, 17‐43 days). Lung function, as measured by spirometry in six patients, remained stable during post‐HCT observation. Six patients (67%) remain alive, with a median follow‐up of 73.5 months. Conclusion Because of toxicity after myeloablative conditioning, RIC is becoming standard for HCT in DKC. These results suggest that RIC regimen is feasible and safe for patients with DKC and does not accelerate pulmonary damage in the short‐to‐medium term after HCT.